Institutional Fund
Davern Capital Partners, LP
Ny, NYCIK 20031472 filings on record
Portfolio Value
$364.54M
Q1 2026
Holdings
17
Reported positions
New Buys
4
Opened this quarter
QoQ Change
+17.9%
from $309.30M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Pfizer Inc12.3%
- Regeneron Pharmaceuticals9.5%
- Insmed Inc8.2%
- Ionis Pharmaceuticals Inc8.0%
- Natera Inc7.9%
- Biontech Se7.4%
- Other46.7%
Portfolio Holdings
17 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Pfizer Inc | 1.59M | $44.76M | 12.3% | −448.3K | Reduced |
| 2 | Regeneron Pharmaceuticals | 44.8K | $34.61M | 9.5% | −7.6K | Reduced |
| 3 | Insmed Inc | 182.6K | $29.85M | 8.2% | +182.6K | New |
| 4 | Ionis Pharmaceuticals Inc | 386.9K | $29.05M | 8.0% | +148.4K | Added |
| 5 | Natera Inc | 144.0K | $28.79M | 7.9% | +65.3K | Added |
| 6 | Biontech Se | 305.1K | $27.11M | 7.4% | −66.2K | Reduced |
| 7 | Argenx Se | 35.0K | $25.59M | 7.0% | −640 | Reduced |
| 8 | Eli Lilly & Co | 27.3K | $25.09M | 6.9% | +19.0K | Added |
| 9 | Royalty Pharma PLC | 520.0K | $24.94M | 6.8% | −320.6K | Reduced |
| 10 | Roivant Sciences Ltd | 873.4K | $24.19M | 6.6% | −154.9K | Reduced |
7 more holdings on Premium
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio